Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
The bill amends the Fair Credit Reporting Act to define “medical debt” and to remove any adverse information related to medical debt from consumer reports. It also directs the Consumer Financial Protection Bureau to revise federal regulations (12 C.F.R. 1022.30) within one year so that creditors are prohibited from obtaining or using information about a consumer’s medical debt when deciding whether to extend credit.
Whether excluding medical debt from consumer reports is primarily a consumer-protection/equity improvement (liberal) or an interference with credit risk assessment that creates moral hazard (conservative).
Relative to its intended legislative type, this bill presents a clear and targeted substantive policy change with concrete statutory amendments and an explicit regulatory deadline, but it omits several implementation and fiscal details that would normally accompany a law that restructures information flows between consumers, furnishers, reporting agencies, and creditors.
The bill amends the Fair Credit Reporting Act to define “medical debt” and to remove any adverse information related to medical debt from consumer reports.
It also directs the Consumer Financial Protection Bureau to revise federal regulations (12 C.F.R. 1022.30) within one year so that creditors are prohibited from obtaining or using information about a consumer’s medical debt when deciding whether to extend credit.
The change covers medical debt broadly (debts arising from receipt of medical services, products, or devices) and eliminates the current exception that allowed certain medical information to appear in consumer reports.
On content alone this is a clear, narrow reform with strong consumer-facing appeal and low direct federal cost, which supports feasibility. Offsetting that, it imposes meaningful regulatory limits on major private-sector actors (credit bureaus, lenders) and lacks compromise mechanisms; those features typically provoke organized opposition and increase difficulty of enactment, especially in the Senate. The prospect of folding the proposal into broader consumer-protection or appropriations packages could materially affect its chances.
Relative to its intended legislative type, this bill presents a clear and targeted substantive policy change with concrete statutory amendments and an explicit regulatory deadline, but it omits several implementation and fiscal details that would normally accompany a law that restructures information flows between consumers, furnishers, reporting agencies, and creditors.
Whether excluding medical debt from consumer reports is primarily a consumer-protection/equity improvement (liberal) or an interference with credit risk assessment that creates moral hazard (conservative).
These are examples from the analysis, not a ranked list of the most-affected groups.
Whether excluding medical debt from consumer reports is primarily a consumer-protection/equity improvement (liberal) or an interference with credit risk assessment that creates moral hazard (conservative).
This persona will generally view the bill positively as a strong consumer-protection measure that prevents medical debt from punishing people’s credit histories.
They will see it as reducing a major source of financial insecurity and a contributor to racial and economic inequities.
They will note that removing medical debt from credit reports can improve access to housing, loans, and employment for people hit by health-related costs.
This persona will see clear consumer benefits in preventing medical debt from harming credit records but will be cautious about trade-offs for lenders and healthcare providers.
They will appreciate the one-year regulatory timeline but will want evidence about impacts on lending risk, credit pricing, and provider finances before full endorsement.
They will favor measured implementation, monitoring, and possibly narrow or technical fixes to prevent gaming or unintended consequences.
This persona will likely oppose the bill as an overreach that interferes with private credit markets and reduces lenders’ access to information needed to assess risk.
They will argue it creates moral hazard by weakening incentives to pay medical bills and may lead to higher borrowing costs for other consumers or insurers.
They will also view the CFPB directive as further expansion of federal regulatory control over private credit transactions.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone this is a clear, narrow reform with strong consumer-facing appeal and low direct federal cost, which supports feasibility. Offsetting that, it imposes meaningful regulatory limits on major private-sector actors (credit bureaus, lenders) and lacks compromise mechanisms; those features typically provoke organized opposition and increase difficulty of enactment, especially in the Senate. The prospect of folding the proposal into broader consumer-protection or appropriations packages could materially affect its chances.
The bill has not accumulated any surfaced votes yet.
Whether excluding medical debt from consumer reports is primarily a consumer-protection/equity improvement (liberal) or an interference wit…
On content alone this is a clear, narrow reform with strong consumer-facing appeal and low direct federal cost, which supports feasibility.…
Relative to its intended legislative type, this bill presents a clear and targeted substantive policy change with concrete statutory amendments and an explicit regulatory deadline, but it omits several implementation an…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.